Sign Up for a Free Account
  • Updated 05.18.2021
  • Released 05.25.2020
  • Expires For CME 05.18.2024

Onasemnogene abeparvovec


Historical note and terminology

Onasemnogene abeparvovec is a gene therapy for delivery of a functional copy of the human survival motor neuron (SMN) gene to the motor neuron cells of patients with spinal muscular atrophy type 1 and is the first gene therapy to be approved for the treatment of spinal muscular atrophy in the United States in May 2019 (06). It was approved by the European Commission in May 2020. It will compete with intrathecal nusinersen, a splice-modulating antisense oligonucleotide, approved for the treatment of spinal muscular atrophy type 1 in 2016.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125